Core Viewpoint - Haleon, after its spin-off from GSK, has successfully navigated market challenges and achieved significant growth in the Chinese market, becoming a standout performer globally [3][5][30] Group 1: Company Overview and Leadership - Haleon was established as a separate entity from GSK in July 2022, inheriting well-known brands like Caltrate and Sensodyne, and has since focused on building a new operational identity [3][5] - The company has seen its market share increase for 54 consecutive months, indicating strong performance in a competitive landscape [3] - Gu Haiying, the General Manager for Mainland China and Hong Kong, emphasizes the importance of leadership and adaptability during periods of transformation [7][8] Group 2: Employee Engagement and Culture - Haleon's employee engagement index has ranked first among its global markets for three consecutive years, reflecting a strong corporate culture [10] - The company prioritizes both "hardware" (systems and processes) and "software" (team cohesion and culture) in its transformation efforts [12] - A focus on communication, trust, and teamwork has been pivotal in unifying the workforce during the integration and spin-off phases [12][13] Group 3: Strategic Initiatives and Market Position - Haleon has positioned China as one of its two "winning markets," implementing a localized decision-making strategy to enhance operational effectiveness [17][18] - The full acquisition of its OTC joint venture marks a significant milestone, allowing for complete control over its operations in China [19][22] - The company is committed to sustainable practices, achieving carbon neutrality in its Suzhou factory and implementing eco-friendly packaging initiatives [24][26] Group 4: Future Directions and Innovations - Haleon is focusing on digital transformation and AI integration, with plans to enhance operational efficiency and product development through technology [28][30] - The company aims to leverage AI not just for cost reduction but to empower and enhance workforce capabilities [28] - Looking ahead, Haleon sees significant opportunities in increasing market penetration in the consumer health sector, addressing gaps in disease occurrence and treatment rates [30]

Core Viewpoint - The news highlights the passing of Guan Ping, a prominent figure in the Chinese pharmaceutical industry, and acknowledges his significant contributions to the sector and various companies he worked with [2][4]. Group 1: Guan Ping's Contributions - Guan Ping was recognized as a senior professional manager in the Chinese pharmaceutical industry, earning accolades such as the "Top Ten Professional Managers" and "Top Ten Pharmaceutical Elites" [4]. - He played a pivotal role in the marketing of major OTC products like Calcium D and Bai Jia Hei, earning the title "Prince of OTC" for his achievements [4][5]. - His career began in 1988 at Xi'an Janssen, where he became the second local pharmaceutical representative, marking the start of his impactful journey in the industry [4]. Group 2: Career Milestones - A significant turning point in Guan Ping's career occurred in 1997 when he joined Wyeth as a regional marketing director, transitioning the company’s focus from hospital sales to the OTC retail market [4][5]. - Under his leadership, sales of Calcium D increased by nearly 20% in 1998, surpassing hospital sales in the retail market [5]. - In 2001, he joined Dongsheng Technology as a director and vice president, where he successfully revitalized the Bai Jia Hei brand, increasing its sales from over 2 million to more than 200 million [5][6]. Group 3: Innovative Strategies - Guan Ping introduced innovative marketing strategies, such as in-store competitions and training for pharmacy staff, which were unprecedented in the industry at the time [5]. - He recognized the challenges faced by pharmaceutical distributors due to shrinking profit margins and implemented a commission-based model in 2002 to enhance profitability for distributors [6]. - By 2004, the sales of the Dongsheng anti-cold family exceeded 50 million, with Bai Jia Hei achieving a record of 500 million [6].

Core Viewpoint - Yuanhe Pharmaceutical announced the unfortunate passing of its director, Mr. Guan Ping, on December 1, 2025, due to an accident, expressing deep condolences and gratitude for his contributions to the company [1][3]. Group 1: Company Information - Mr. Guan Ping held 500,000 shares of Yuanhe Pharmaceutical, representing 0.81% of the company's total equity [3]. - The company and its employees paid high respect and heartfelt thanks to Mr. Guan for his hard work and outstanding contributions during his tenure [3]. Group 2: Industry Background - Mr. Guan Ping was a seasoned professional in the Chinese pharmaceutical industry, recognized as one of the top ten professional managers and pharmaceutical elites, earning the nickname "Prince of OTC" for his significant contributions to the OTC market [5][6]. - His career included key positions at major pharmaceutical companies such as Xi'an Janssen, Lizhu Group, Wyeth, Shijiazhuang Pharmaceutical Group, and Dongsheng Technology, where he played a pivotal role in launching successful products like Calcium D and Bai Jia Hei [5][6][7]. - Mr. Guan's innovative marketing strategies, such as in-store promotions and training for pharmacy staff, significantly boosted sales, exemplified by the increase in sales of Calcium D by nearly 20% in 1998 [6][7].

Group 1 - Haleon showcased over 70 core products at the China International Import Expo, including 11 new products and 3 global debuts, emphasizing its deep localization strategy in the Chinese market [1] - The company aims to achieve a threefold "spillover effect" through the expo, transitioning from exhibits to products, brands to ecosystems, and local to global [3] - Haleon has established a digital health management ecosystem by collaborating with platforms like JD Health and Ping An Good Doctor, focusing on a new health consumption model that integrates products, services, and platforms [6] Group 2 - The "China Consumer Active Health Insight Report" released by Haleon indicates a shift in public health awareness in China from passive response to active management, although a gap between knowledge and action remains [4] - Haleon has enhanced its local operational capabilities through the acquisition of Tianjin SmithKline and expansion in Suzhou, aiming to create an agile operational system to better respond to market demands [6]

Core Insights - Haleon showcased over 70 core products at the China International Import Expo, emphasizing its commitment to the Chinese market with a focus on "proactive health" [1] - The company aims to leverage the expo as a platform for product innovation and to enhance consumer trust in its brand through scientific demonstrations and ESG initiatives [2] - Haleon has established deep collaborations with digital health platforms like JD Health and Ping An Good Doctor to create a new health consumption model centered on lifecycle management [3] Group 1 - Haleon presented 11 new products and 3 global debuts at the expo, highlighting its strategic localization efforts in China [1] - The company reported a shift in Chinese consumer health awareness from passive to proactive management, despite existing challenges in translating knowledge into action [2] - Digital health management tools were introduced at the expo to promote the idea that individuals are responsible for their own health [2] Group 2 - Haleon's acquisition of Tianjin SmithKline and expansion in Suzhou are aimed at enhancing local operational capabilities and creating an agile supply chain [3] - The collaboration with digital health platforms is designed to build a data-driven ecosystem focused on comprehensive health management [3] - The strategic goal of the Tianjin and Suzhou operations is to create a unified agile operating system to better respond to market demands in China [3]

Group 1 - Nearly 70% of British companies in China are optimistic about their business prospects over the next 5 to 10 years and plan to increase investments in China [1][6] - The UK is China's second-largest trading partner after the US, highlighting the importance of the Chinese market for global brands [3][6] - The shift in Chinese consumer behavior from "purchasing" to "experiencing" brands emphasizes the need for companies to focus on the experiential aspect of their products [3][5] Group 2 - The presence of social media has simplified market entry for companies, allowing them to focus on online platforms rather than traditional brick-and-mortar stores [4][5] - The Chinese government has implemented policies to boost domestic consumption and reduce market entry barriers, which are beneficial for foreign businesses [5][6] - The UK-China trade relationship is characterized by strong complementarity, with the UK being a significant investment destination for Chinese companies [6][8] Group 3 - The UK government has suspended tariffs on 89 products to alleviate the burden on businesses, which is expected to save around £17 million annually [7] - The British market, while smaller than China's, remains vibrant and open, providing opportunities for international brands [6][7] - The British Chamber of Commerce is actively working to assist small and medium-sized enterprises (SMEs) in entering the Chinese market [6]